Pharmaceutical company Crossject (Euronext Growth Paris:ALCJ) announced on Tuesday the development and upcoming implementation of the ZENEO Nest, a new manufacturing module designed to enhance the aseptic filling process of its proprietary ZENEO drug-delivery device.

The ZENEO Nest automates and increases the volume of batch aseptic filling for the device's glass drug container, significantly improving manufacturing scalability within partner contract development and manufacturing organisations (CDMOs).

This innovation supports Crossject's strategy to prepare for large-scale deployment of ZEPIZURE, its lead emergency treatment for epilepsy, and other pipeline products.

ZENEO Nest is engineered for compatibility with diverse filling equipment, enabling flexible deployment at CDMO sites in France and internationally as demand scales.

The first system was successfully tested with EUROFINS, which will be the initial user of the module. Full implementation at its Dijon facility is targeted for December 2025, with qualification and validation expected by the first quarter of 2026.